Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 27, 2014

ImaCor introduces all-in-one haemodynamic management platform

US-based developer of haemodynamic transesophageal echocardiography (hTEE) technology ImaCor has launched its all-in-one platform for advanced haemodynamic management, including hTEE, hTTE and the Zura ultrasound systems.

Imacor

US-based developer of haemodynamic transesophageal echocardiography (hTEE) technology ImaCor has launched its all-in-one platform for advanced haemodynamic management, including hTEE, hTTE and the Zura ultrasound systems.

The company said that hTEE is enabled by the ClariTEE probe, which can be left indwelling for 72 hours, while hTTE is a transthoracic probe for complementary haemodynamic management.

The Zura ultrasound systems, including the Zura EVO-1, which is the latest model in the Zura EVO family, provide new advanced processing for high-definition imaging.

Thomas Jefferson University Hospital director of the Surgical Critical Care Unit Nicholas Cavarocchi said: "I am impressed with the significant image quality improvements on ImaCor’s all-in-one haemodynamic management platform; it provides the whole picture in critical care."

The company’s haemodynamic management platform also includes haemodynamic trending, displaying cardiac filling and function data over time in a dashboard format.

Additional features include sizeable image quality improvements with a 7mHz resolution at 18cm depth.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

ImaCor president and CEO Peter Pellerito said: "Strategically, our all-in-one haemodynamic management platform fulfils our vision of providing the most advanced technology in critical care.

"The new system delivers a higher level of capabilities to our customers, avoiding dramatic cost, while saving time, money, and ultimately, lives."

Meanwhile, the US Food and Drug Administration (FDA) has granted the company’s transthoracic echocardiography (TTE) probe 510(k) clearance, making its platform the first-of-its-kind for haemodynamic management.


Image: ImaCor all-in-one haemodynamic management platform with hTEE technology enabled by a ClariTEE probe and 510(K) cleared hTTE probe. Photo: courtesy of Business Wire.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU